Case Report

Hypothyroidism Complicating Nephropathy in a Diabetes Patient

Jayaprakash Sahoo, Ilangovan Veerappan, Anila Abraham, and Somasundaram Hariharan

1 Department of Endocrinology, Pondicherry Institute of Medical Sciences, Puducherry 605014, India
2 Department of Nephrology, Pondicherry Institute of Medical Sciences, Puducherry 605014, India
3 Department of Pathology, Madras Medical Mission, Chennai 600037, India

Correspondence should be addressed to Jayaprakash Sahoo, jppgi@yahoo.com

Received 1 October 2012; Accepted 11 November 2012

1. Introduction

Type 2 diabetes mellitus is associated with various components of metabolic syndrome like obesity, hypertension, and dyslipidemia [1]. Hypothyroidism also leads to secondary dyslipidemia [2]. Drugs used for treatment of dyslipidemia like statins and fibrates cause myalgia, myopathy, and rhabdomyolysis with renal injury particularly in the presence of hypothyroidism [3]. This case report discusses the above complications in a diabetes patient with primary hypothyroidism and also the renal response to thyroxine supplementation.

2. Case Report

A forty-year-old male having diabetes mellitus for six years came with complaints of pain in both lower limbs. He was neither a smoker nor an alcoholic and had family history of diabetes mellitus with chronic kidney disease. He was a teacher by occupation with sedentary lifestyle and was compliant with diabetic diet. There was no history of hypertension, coronary artery disease, transient ischemic attacks/cerebrovascular accident, and recurrent urinary tract infection, and he was not evaluated for microvascular complications like nephropathy/retinopathy. He was denying the intake of any nephrotoxic drug in the past. Glycemic control was fair (HbA1c, 6.7%) with oral hypoglycaemic agents (one gram of Metformin and one milligram of Glimepiride). On examination, he was overweight (BMI, 24) with sensory neuropathy (lower limbs > upper limb) and blood pressure of 110/70 mmHg with palpable peripherals pulses. There was neither goiter nor any sign of hypothyroidism.

The patient had normal reports of ECG, 2D echocardiography, and arterial doppler of lower limbs. But the lipid profile and renal function test were deranged (Table 1). We added Pregabalin (75 mg) for sensory neuropathy and Atorvastatin (10 mg) and Fenofibrate (145 mg) for dyslipidemia. The patient came after four and half months with reports that showed primary hypothyroidism due to Hashimoto’s thyroiditis (Table 1) with urine spot protein creatinine ratio of 1.6 and normal ultrasound findings of kidneys/ureter/bladder. There was no evidence of diabetic retinopathy. But additionally, there was elevated serum aspartate aminotransferase (SGOT) level. Hypolipidemic drug complicating hypothyroidism-induced muscle damage was suspected and was confirmed by increased serum
Table 1: Investigations at different time points.

<table>
<thead>
<tr>
<th></th>
<th>~4.5 months</th>
<th>0 time</th>
<th>+1 month</th>
<th>+4 months</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum TSH</td>
<td>—</td>
<td>160</td>
<td>09</td>
<td>04</td>
<td>0.27–4.2 mIU/L</td>
</tr>
<tr>
<td>TPO antibody</td>
<td>—</td>
<td>&gt;500</td>
<td>—</td>
<td>—</td>
<td>&lt;40 IU/L</td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>381</td>
<td>220</td>
<td>254</td>
<td>259</td>
<td>&lt;200 mg%</td>
</tr>
<tr>
<td>Triglyceride</td>
<td>1286</td>
<td>250</td>
<td>619</td>
<td>280</td>
<td>&lt;150 mg%</td>
</tr>
<tr>
<td>LDL</td>
<td>—</td>
<td>119</td>
<td>—</td>
<td>148</td>
<td>&lt;100 mg%</td>
</tr>
<tr>
<td>HDL</td>
<td>16</td>
<td>51</td>
<td>26</td>
<td>55</td>
<td>&gt;40 mg%</td>
</tr>
<tr>
<td>HbA1c</td>
<td>6.7%</td>
<td>7.2%</td>
<td>—</td>
<td>—</td>
<td>6%-7%</td>
</tr>
<tr>
<td>Serum creatinine</td>
<td>1.5</td>
<td>1.6</td>
<td>1.1</td>
<td>1.1</td>
<td>0.6–1.2 mg%</td>
</tr>
<tr>
<td>*MDRD eGFR</td>
<td>55</td>
<td>51</td>
<td>79</td>
<td>79</td>
<td>≥90 mL/min per 1.73 m²</td>
</tr>
<tr>
<td>Serum CPK</td>
<td>—</td>
<td>2810</td>
<td>104</td>
<td>—</td>
<td>25–200 IU/L</td>
</tr>
<tr>
<td>Serum LDH</td>
<td>—</td>
<td>549</td>
<td>378</td>
<td>—</td>
<td>225–420 IU/L</td>
</tr>
<tr>
<td>Serum SGOT</td>
<td>—</td>
<td>201</td>
<td>15</td>
<td>—</td>
<td>&lt;37 IU/L</td>
</tr>
<tr>
<td>Serum SGPT</td>
<td>—</td>
<td>66</td>
<td>—</td>
<td>—</td>
<td>&lt;65 IU/L</td>
</tr>
<tr>
<td>Serum K⁺</td>
<td>—</td>
<td>5.5</td>
<td>4.4</td>
<td>4.3</td>
<td>3.5–5 meq/L</td>
</tr>
<tr>
<td>Serum albumin</td>
<td>—</td>
<td>4.2</td>
<td>4.2</td>
<td>4.0</td>
<td>4-5 gm%</td>
</tr>
<tr>
<td>Urine protein/creatinine ratio</td>
<td>—</td>
<td>1.6</td>
<td>1.0</td>
<td>1.0</td>
<td>&lt;0.3</td>
</tr>
<tr>
<td>Urine microscopy</td>
<td>—</td>
<td>4-5 pus cells/HPF</td>
<td>8–10 pus cells/HPF</td>
<td>4–6 pus cells/HPF</td>
<td>0–2 pus cell/HPF</td>
</tr>
<tr>
<td>Urine C/S</td>
<td>—</td>
<td>Sterile</td>
<td>Sterile</td>
<td>—</td>
<td>Sterile</td>
</tr>
</tbody>
</table>

*MDRD eGFR: Modification of diet in renal disease estimated glomerular filtration rate.

Creatine phosphokinase (CPK) and lactate dehydrogenase (LDH) level. But there was no history of myalgia, myopathy, decrease in urine output, or cola-coloured urine. The hypolipidemic drugs were stopped, and he was started on thyroxine supplementation.

A renal biopsy was done due to abnormal renal function, proteinuria in the absence of retinopathy, and a positive family history of chronic kidney disease. The glomeruli were normocellular with mildly thickened basement membranes and mild mesangial matrix expansion (Figure 1). There were no spikes or duplication of the basement membrane. The tubular epithelial cells showed cytoplasmic vacuolization and sloughing. There was no pigment casts seen. There was focal interstitial fibrosis and tubular atrophy involving about 20% of the core. There was arteriolar hyalinosis and mild medial hyperplasia of the arteries. The features were consistent with early diabetic nephropathy (class-IIa) [4]. The electron microscopy showed mild-to-moderate basement membrane thickening with mild segmental mesangial expansion without any evidence of immune complex deposition. Additionally, there was prominent diffuse isometric tubular cytoplasmic vacuolization.

The patient was started on Telmisartan (20 mg) with periodic monitoring of serum creatinine, potassium, and urine routine/microscopic examination. Repeat investigations (Table 1) revealed normal CPK, LDH, and SGOT with improving serum creatinine and proteinuria.

### 3. Discussion

Severe hypothyroidism (biochemically) may be completely asymptomatic. Though our patient had TSH level more than 100 mIU/L, he did not have any symptoms of hypothyroidism. Jarløv et al. had reported earlier that diagnosis of hypothyroidism depends on laboratory parameters rather than clinical findings [5]. In an analysis of patients with varying degrees of hypothyroidism, Zulewski et al. highlighted the discordance between biochemical and clinical hypothyroidism. Some patients with severe biochemical hypothyroidism had only mild clinical manifestations, whereas other patients with trivial biochemical changes had quite severe physical signs and symptoms [6]. So, it appears that there can be complete dissociation between the biochemical hypothyroidism and tissue hypothyroidism at the peripheral target organs in an individual patient.

Hypolipidemic drugs do not precipitate rhabdomyolysis in all hypothyroid patients. The exact incidence and the mechanisms are not clear [3]. The total CPK was elevated and the SGOT:SGPT ratio was more than three, both...
suggesting muscle injury in this case. The muscle injury was not of significant degree to precipitate pigment-induced acute tubular injury as evidenced by relatively stable serum creatinine in the period when the patient was taking the hypolipidemic drugs. Impaired glycogenolysis and mitochondrial oxidative metabolism are possible mechanisms for rhabdomyolysis in hypothyroid patients [7]. The theory behind statin-induced muscle injury is skeletal muscle cell membrane instability due to reduced small GTP (guanosine 5′- triphosphate) binding proteins and cholesterol synthesis, which is exaggerated by addition of fibrates [8]. Classically, rhabdomyolysis is associated with muscle pain and weakness with increased muscle enzymes in the serum [9]. But it may be totally asymptomatic like the index case. The only clue for muscle damage in our patient was increased isolated serum SGOT level, which was confirmed by increased level of other muscle enzymes (CPK & LDH).

There are multiple reasons for reduction in GFR in patients with hypothyroidism: reduced renal blood flow [10], increased peripheral vascular resistance [11], and intrarenal vasoconstriction due to reduced renal response to vaso-dilators [12, 13]. There is also reduced expression of renal vasodilators like vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) [14]. Additionally, there is decreased renin release [15] and impaired renin angiotensin aldosterone system activity which contributes to reduced GFR [16]. It has been reported that there is decrease in tubular secretion of creatinine—a process mediated by the thyroid hormones via the Na+/Ca2+ exchanger and the Na+/K+ ATPase activity further contributing to increase in serum creatinine [17]. Additionally, hypothyroidism leads to changes similar to early diabetic nephropathy like thickening of glomerular and tubular basement membrane with expanded mesangial matrix which is responsible for glomerular leaking of proteins [18–20].

Within one month after starting thyroxine supplementation along with withdrawal of the hypolipidemic drugs, the serum creatinine decreased from 1.6 mg/dL to 1.1 mg/dL with some improvement in proteinuria (Table 1). However, serum creatinine and proteinuria remained static for next 3 months in spite of continuation of thyroxine replacement. The initial improvement in renal parameters was due to both correction of rhabdomyolysis and hypothyroidism. The residual renal dysfunction may be due to presence of underlying diabetic nephropathy. But the absence of retinopathy in this case makes diabetic nephropathy less likely as a cause for renal dysfunction, which will be confirmed during further followup.

4. Conclusion

The correlation between serum TSH, tissue hypothyroidism, and clinical features is poor. Hypothyroidism-induced rhabdomyolysis with or without associated statin/fibrate therapy may lead to abnormal renal function in a diabetes patient. Additionally, hypothyroidism also causes renal changes similar to early diabetic nephropathy. This should be kept as one differential diagnosis for reversible renal dysfunction in a diabetes patient.

Conflict of Interests

The authors declare no conflict of interests.

Acknowledgment

The authors acknowledge the help of Alexis A. Harris (Nephropath, Arkansas, USA) for assistance in processing electron microscopy of renal biopsy specimen.

References


Submit your manuscripts at http://www.hindawi.com